Fasiglifam
TAK-875_203
Phase 3 small_molecule terminated
Quick answer
Fasiglifam for Type 2 Diabetes Mellitus is a Phase 3 program (small_molecule) at Takeda Pharmaceuticals International AG with 2 ClinicalTrials.gov record(s).
Program details
- Company
- Takeda Pharmaceuticals International AG
- Indication
- Type 2 Diabetes Mellitus
- Phase
- Phase 3
- Modality
- small_molecule
- Status
- terminated